FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Drugs & Pharmacology | Food and Drug Administration (FDA)